Discovery May Lead to a Treatment to Slow Parkinson's Disease
Interaction between a mutant gene and alpha synuclein leads to hallmark Parkinson’s pathologies
In this study, researchers were able to see that LRRK2, a mutant kinase enzyme that is the most common genetic cause for Parkinson’s disease, can cause the buildup of inclusions in neurons. These inclusions are one of the main pathologies seen in patients with Parkinson’s disease. New drugs that are currently being developed for clinical use would inhibit the buildup of inclusions stopping the aggregated alpha synuclein protein which would slow the progression of the disease. To read more, click here.
GOODMAN Oral Board Preparation Course Tumor
Nov. 1-3, 2017; Glendale, Ariz.
June 29-30, 2017; Germany
2nd International Conference on Spine and Spinal Disorders
July 24-26, 2017; Rome, Italy
The Society of University Neurosurgeons Annual Meeting
July 27-Aug. 3, 2017; South Africa
Washington University/St. Louis Children’s Comprehensive SEEG Course
Aug. 10-12, 2017; St. Louis